Quoin Pharmaceuticals, Ltd.
QNRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,281 | $2,051 | $2,374 | $1,070 |
| G&A Expenses | $1,739 | $1,743 | $1,583 | $1,335 |
| SG&A Expenses | $1,739 | $1,743 | $1,583 | $1,335 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,020 | $3,793 | $3,957 | $2,405 |
| Operating Income | -$4,020 | -$3,793 | -$3,957 | -$2,405 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $72 | $97 | $145 | $94 |
| Pre-Tax Income | -$3,948 | -$3,696 | -$3,812 | -$2,311 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,948 | -$3,696 | -$3,812 | -$2,311 |
| % Margin | – | – | – | – |
| EPS | -6.71 | -6.28 | -6.5 | -12.37 |
| % Growth | -6.8% | 3.4% | 47.5% | – |
| EPS Diluted | -6.71 | -6.28 | -6.5 | -12.41 |
| Weighted Avg Shares Out | 588 | 588 | 586 | 187 |
| Weighted Avg Shares Out Dil | 588 | 588 | 586 | 187 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $105 | $145 | $109 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $25 | $25 | $25 | $25 |
| EBITDA | -$3,923 | -$3,768 | -$3,932 | -$2,380 |
| % Margin | – | – | – | – |